Navigation Links
New topical approach to treating nail fungus circumvents problems with current therapy
Date:10/28/2008

WASHINGTON, D.C. (October 27, 2008) A novel topical therapy for nail fungus, NB-002, has demonstrated a new topical approach to healing nail fungus by penetrating skin pores and diffusing through the skin that surrounds the entire nail plate, according to a study conducted by NanoBio Corporation.

The data represent a unique approach to treating nail fungus (onychomycosis), which resists topical therapies because they cannot penetrate the nail and access the site of infection. The results were reported this morning at the 48th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting in Washington, D.C.

"In testing NB-002 on human cadaver skin, we have demonstrated that the lotion permeates and then laterally diffuses across tissue plains in the epidermis and the dermis to more than 1 centimeter away from the site of application," said Susan Ciotti, Ph.D., director of formulations and research and development, and presenting author of the data.

"The average great toenail measures 22 millimeters across, so we are able to deliver NB-002 across the entire span of an infected human large toenail, a huge advance in the treatment of onychomycosis," Ciotti said.

Because of its novel mode of penetration and diffusion, NB-002 is able to achieve 50 times the minimum drug concentration required to kill the fungus in the very center of the nail bed. Only 4 micrograms per gram of tissue are required for NB-002 to kill fungal infections.

Newer, more effective therapies for nail fungus are important because onychomycosis remains a large unmet medical need, according to the NanoBio scientists. Oral systemic medications are plagued by serious hepatic and cardiac toxicity concerns, while current topical medications are not effective because they are unable to penetrate to the site of infection.

"The safe and efficient delivery of NB-002 makes it an ideal candidate for the treatment of onychomycosis," Ciotti said. "And because there is no systemic absorption, NB-002 does not pose the risk of adverse events or drug interactions that systemic antifungal agents present."

NB-002 kills both active spores and developing hyphae, an additive effect that lessens the fungi's ability to survive in human tissue, said James R. Baker, Jr., M.D., founder and chairman of NanoBio Corp. Studies conducted in vitro demonstrate that NB-002 has robust antifungal activity against all organisms that cause nail fungus, including Trichophyton rubrum, T. mentagrophytes, Epidermophyton floccosum, Microsporum canis and Candida albicans.

NanoBio scientists credit the topical lotion's safety and robust anti-infective activity to NB-002's novel technology platform. The lotion is composed of an oil-in-water emulsion and a commonly used antimicrobial surfactant that are mixed at high speeds to nanosize the particles and infuse them with high levels of potential energy. The resulting nanodroplets easily penetrate hair follicles and skin pores to reach the site of infection without damaging or irritating skin or mucous membranes. Upon contact with the pathogen, the highly charged particles release their energy to the pathogen's outer membranes, disrupting the fungus.

NB-002 is currently being studied in a randomized, double-blind, placebo-controlled, phase 2 trial in more than 400 subjects with onychomycosis. Final results are expected in the first quarter of 2009.


'/>"/>

Contact: Becky Levine
blevine@medthink.com
919-786-4918
MedThink Communications
Source:Eurekalert

Related medicine news :

1. Topical treatment for cold sores achieves efficacy of oral drugs; represents paradigm shift
2. Topical oral syrup prevents early childhood caries
3. Nuvo licenses topical pain product from Paladin
4. Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder
5. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
6. Fougera First-to-Market With Calcipotriene Topical Solution 0.005% (Rx) (Scalp Solution)
7. ImQuest Presents New Anti-HIV Drug and Topical Microbicide Development Results on Lead Pyrimidinedione Products IQP-0410 and IQP-0528
8. Topical Cream Treats Precancerous Lesions of Vulva
9. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
10. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
11. Summit VetPharm Introduces New Feline Topicals Vectra(TM) for Cats & Kittens and Vectra(TM) for Cats
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... South Hills of Pittsburgh now have easier access to the robotic-assisted total-hip ... Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital ...
(Date:3/29/2017)... ... ... VisualSP has helped over 1.5 million SharePoint users learn the content management system ... Help System for SharePoint was at the farm level. Enterprises using SharePoint Online in ... The company recently released a modified version of the Help System, VisualSP for Site ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati Technologies announced today ... the resolution to globally reduce the harmful use of alcohol set forth by ... TTB approved ingredients that when infused into alcohol, renders the alcohol liver and ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret is ... Pharm.D., FASCP. The program was recently launched on March 1, and Dr. Wentz ... function. , Dr. Izabella Wentz is a licensed pharmacist and a foremost ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... dedicated to advancing the science and clinical practice of radiosurgery, announced today ... Registry, a multi-institutional, observational registry established to standardize data collection from patients ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical ... non-invasive medical devices for pain management, stroke rehabilitation, cardiac ... host the Company,s 2016 full-year investor webcast on Monday, April ... The Company expects to file its 2016 full ... ...
(Date:3/29/2017)... , March 29, 2017 Optometrists ... patients as the highest standard in quality and ... Vision introduces its objective Wavefront-driven refraction technologies and ... approach. This enables an unprecedented level of refraction ... exceptional vision relegated to Topgun Navy fighter pilots, ...
(Date:3/29/2017)... March 29, 2017 According to a new market ... (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, Badges), ... published by MarketsandMarkets, the market is expected to reach USD 1,215.4 Million ... 6.5% from 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology: